Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Descriptive statistics for all demographic, anthropometric and disease-related outcomes in patients with axial spondyloarthritis (n = 170)

From: Widespread pain in axial spondyloarthritis: clinical importance and gender differences

Variables Total group (n = 170) Men (n = 108) Women (n = 62)  
Mean (SD) Med (IQR) Mean (SD) Med (IQR) Mean (SD) Med (IQR) p Value
Age, yr 42.9 (12.2) 42.7 (20.3) 43.8 (12.5) 43.2 (20.4) 41.3 (11.5) 42.1 (18.0) .199
Disease duration, yr 13.1 (11.1) 10.7 (16.6) 14.0 (11.2) 11.9 (18.4) 11.5 (11.0) 8.8 (13.0) .155
Height, cm 171.6 (9.4) 172.3 (12.9) 176.2 (7.1) 176.2 (9.1) 163.7 (7.4) 163.4 (9.5) < .00
Weight, kg 77.0 (15.0) 76.6 (20.9) 81.7 (13.9) 80.5 (19.2) 69.7 (13.4) 67.0 (18.1) < .00
BMI, kg/m2 26.1 (4.4) 25.6 (6.4) 26.3 (4.4) 25.5 (6.1) 25.7 (4.4) 25.7 (7.1) .408
BASDAI (0–10) 3.8 (2.1) 3.7 (3.3) 3.6 (2.2) 3.5 (3.5) 4.3 (2.0) 4.2 (3.1) .027
PGDA (0–10) (n = 146) 1.4 (1.8) 1.0 (2.0) 1.4 (1.9) 0.9 (2.0) 1.4 (1.6) 1.0 (1.6) .583
CRP, mg/L (n = 141) 8.3 (16.0) 2.9 (6.6) 8.9 (16.5) 3.0 (6.6) 7.4 (15.3) 2.2 (6.7) .810
BASFI (0–10) 3.6 (2.4) 3.4 (3.8) 3.5 (2.4) 3.2 (4.0) 3.8 (2.3) 3.7 (3.7) .459
BASMI (0–10) 3.0 (1.8) 2.8 (2.0) 3.3 (2.0) 2.8 (2.8) 2.6 (1.2) 2.6 (1.6) .002
Cervical rotation, degrees 60.5 (19.6) 65.0 (25.0) 58.0 (21.3) 62.5 (27.8) 65.0 (15.6) 66.0 (20.5) .015
Tragus to wall, cm 13.6 (4.6) 11.7 (4.5) 14.9 (5.0) 13.3 (6.2) 11.4 (2.3) 10.8 (1.8) < .00
Lateral flexion, cm 12.4 (5.1) 12.7 (8.1) 11.7 (6.1) 12.1 (9.4) 13.5 (4.2) 13.1 (6.1) .028
Intermalleolar distance, cm 99.0 (22.6) 103.3 (25.1) 101.0 (21.4) 105.2 (25.2) 95.5 (24.2) 100.7 (25.0) .141
Modified Schober, cm 5.3 (2.1) 5.5 (2.5) 4.9 (2.3) 5.2 (3.1) 5.9 (1.7) 6.2 (2.0) .002
TSK-11 (11–44) 24.8 (6.3) 25.0 (10.0) 27.8 (6.4) 25.0 (10.0) 24.9 (6.0) 25.0 (9.3) .888
HADS depression (0–21) 4.6 (3.6) 4.0 (5.0) 4.8 (3.7) 4.0 (5.0) 4.4 (3.5) 3.0 (4.0) .580
HADS anxiety (0–21) 7.1 (3.6) 7.0 (5.0) 6.7 (3.4) 7.0 (5.0) 7.8 (3.9) 7.5 (5.0) .071
Frequencies (%)
Gender, male/female 108/62 (64/36) NA NA NA
NSAIDs, yes/no 87/83 (51/49) 56/52 (52/48) 31/31 (50/50) .816
Biologicals, yes/no 67/103 (39/61) 45/63 (42/58) 22/40 (36/64) .427
Corticosteroids, yes/no 12/158 (7/93) 6/102 (6/94) 6/56 (10/90) .313a
DMARDs, yes/no 71/99 (42/58) 43/65 (40/60) 28/34 (45/55) .496
Psychopharmacologic agents, yes/no 12/158 (7/93) 6/102 (6/94) 6/56 (10/90) .313a
Analgesics, yes/no 73/97 (43/57) 33/75 (31/69) 40/22 (65/35) < .00
Work status, yes/nob 99/64 (61/39) 64/38 (63/37) 35/26 (57/43) .497
  1. Abbreviations: BMI Body mass index, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, normal value < 5 mg/L, HADS Hospital Anxiety and Depression Scale, NSAIDs Non-steroidal anti-inflammatory drugs, DMARDs Disease-modifying anti-rheumatic drugs, p<.05
  2. ap Value based on phi coefficient instead of chi Square test
  3. bn = 163 (9 males, 2 females missing)